Subcutaneous amivantamab caused far fewer infusion-related reactions than intravenous dosing.
Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast.
Danny Nguyen
Targeted oncology · Aug 2026
Purpose
Response rate (objective response rate) was 30% in the subcutaneous group and 33% in the intravenous group; median progression-free survival was 6.1 and 4.3 months, respectively.
Results
Subcutaneous dosing sharply cut infusion reactions versus intravenous
SC IRR
13%
IV IRR
66%
More results
In the PALOMA-3 study, subcutaneous (subcutaneous) amivantamab was investigated to improve tolerability, reduce administration time, maintain efficacy, and improve patient experience.
More results
The PALOMA-3 study investigated the noninferiority of pharmacokinetics, with other endpoints including efficacy and safety of subcutaneous versus intravenous amivantamab, combined with lazertinib in participants with epidermal growth factor receptor-mutated, advanced nonsmall cell lung cancer after disease progression on osimertinib and platinum-based chemotherapy.
“
Conclusion
Utilizing subcutaneous amivantamab, while optimizing treatment efficacy and safety through mitigating and managing adverse events, may enhance the patient experience.